NCT06120361 · RECRUITING
The Swedish BioFINDER - Primary Care Study
This Swedish study is testing whether blood-based biomarkers and cognitive assessments can accurately detect Alzheimer's disease and other forms of cognitive decline in ordinary primary care settings, before patients are referred to specialist memory clinics. It is not a drug trial — no treatments are being given. There is no specified phase because it is an observational diagnostic study, meaning researchers are watching and measuring, not intervening.
You may qualify if
- The patient seeks medical help because of cognitive symptoms experienced by the patient and/or informant OR The general practitioner suspects a progressive neurodegenerative disorder including, but not limited to, Alzheimer's disease, Lewy body disease, frontotemporal lobar degeneration or subcortical vascular cognitive impairment.
- The main symptom is usually memory complaints, but could also be executive, visuo-spatial, language, or attention complaints.
- Age ≥40 years
- Subjective cognitive decline, mild cognitive impairment or mild dementia
You're excluded if
- Already diagnosed dementia
- Significant unstable systemic illness or organ failure that makes it difficult to participate.
- Current significant alcohol or substance misuse.
- Refusing investigation at the Memory clinic
- Cognitive impairment with acute onset due to stroke
- The cognitive impairment can with certainty be explained by another condition or disease such as significant anemia, infection, severe sleep deprivation, psychotic disorder, moderate-severe depression, alcohol abuse etc.
The sponsor's own eligibility wording, lightly reformatted. The study team makes the final eligibility decision — worth discussing with your doctor.
Eligibility criteria as of 2026-04-06